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ABSTRACT 
Background: Maternal serum 25-hydroxyvitamin D (25(OH)D) deficiency in pregnancy has 
been associated with decreased infant birth weight, although research has not been consistent. No 
research is available investigating the effects of serum 25(OH)D on estimated fetal weight 
(EFW). Only one study has been published relating infant body composition to maternal serum 
vitamin D status.  
 
Purpose: The purpose of this study was to further investigate the relationship between maternal 
serum 25(OH)D and fetal growth and neonate body composition. 
 
Methods: Sixty-three pregnant women had serum 25(OH)D analyzed late in pregnancy. Percent 
fat (%fat), fat mass (FM), and fat free mass (FFM) of the offspring were analyzed using air 
displacement plethysmography within 72 hours of life. Multiple linear regression was used to 
assess the relationship between maternal 25(OH)D and infant body composition. Covariates 
considered included pre-pregnancy body mass index (BMI), total gestational weight gain 
(GWG), infant gender, and infant age at test. Fifty-six and 31 participants had data estimating 
fetal weight in early and late gestation, respectively. The relationship between maternal serum 
25(OH)D and EFW was assessed using multiple linear regression. Covariates considered in this 
analysis were pre-pregnancy BMI, GWG up to sonogram measurement, gestational age (GA) at 
measurement, and infant gender.  
 
Results: The mean serum 25(OH)D of the sample was 52.6 nmol/L, with 50.7% below 
50nmol/L, which is defined as deficient by the Endocrine Society. Across classification groups 
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those classified as serum 25(OH)D deficient had significantly higher pre-pregnancy BMIs, than 
those that were classified as having adequate or insufficient serum 25(OH)D. Gestational age at 
birth was the only predictor of infant birth weight (β= 171.050, p= 0.005). Infant %fat and FM 
were both predicted by age at test alone (β= 1.61, p = 0.037; β=  87.45, p= 0.004). FFM was 
predicted by infant age at test (β= 158.24, p= 0.001), gender (β= - 197.34, p= 0.004), and GA at 
birth (β= 194.37, p<0.001). EFW early in pregnancy was predicted by GWG (β= -3.84, p= 
0.006) and GA at measurement (β= 65.65, p< 0.001). Only GA predicted EFW late in pregnancy 
(β= 208.83, p< 0.001). Maternal 25(OH)D did not remain significant in any of the variables. 
 
Conclusion: Maternal serum 25(OH)D was not a predictor of birth weight, infant %fat, FM, 
FFM, or EFW in early or late pregnancy. 
 
 
v 
ACKNOWLEDGEMENTS 
 I would like to thank my mentor Holly Hull, PhD for her assistance in developing and 
writing this thesis. I would also like to express my appreciation for the numerous opportunities 
that she has given me throughout my graduate study. Dr. Hull, thank you for helping me to 
develop my skills as a writer, researcher and nutrition professional. Furthermore, I would like to 
thank Susan Carlson, PhD and Debra Sullivan, RD, PhD for their participation on my thesis 
committee. It truly has been an honor to work with you both.  
 Special thanks go to the members of Dr. Hull’s laboratory. I’d like to thank Shengqi Li, 
MS, PhD candidate and Cheng Li, MS for their work on the Epic Study and assistance in 
preparing this thesis. Thank you to Megan Brinker, RD, Emily Newbold, RD, Brianna Helfrich 
and Mira Dewi for your work with the Thrasher Study. 
 Finally, I would like to thank my family and friends for being my cheerleaders and 
support throughout my education. Without your help from my first days of school, I definitely 
would not be here. Thank You! 
 
 
vi 
Table of Contents 
Chapter I: Introduction .................................................................................................................... 1 
Statement of Purpose ................................................................................................................... 2 
Research Question ....................................................................................................................... 2 
Specific aims and Hypotheses ..................................................................................................... 2 
Special Note ................................................................................................................................ 3 
Chapter II: Literature Review ......................................................................................................... 4 
Vitamin D: The sunshine vitamin ............................................................................................... 4 
Metabolic pathway for synthesis ............................................................................................. 4 
Regulation of Vitamin D synthesis .......................................................................................... 5 
Vitamin D receptor .................................................................................................................. 6 
Food sources of vitamin D ....................................................................................................... 7 
Vitamin D’s role in health ........................................................................................................... 8 
Bone health .............................................................................................................................. 8 
Inflammation ........................................................................................................................... 9 
Cardiovascular disease ............................................................................................................ 9 
Type 2 Diabetes ..................................................................................................................... 10 
Vitamin D and maternal health during pregnancy .................................................................... 11 
Gestational diabetes ............................................................................................................... 11 
Maternal obesity and vitamin D deficiency .............................................................................. 13 
Recommendations for vitamin D intake during pregnancy ...................................................... 14 
Rates of insufficiency or deficiency during pregnancy ......................................................... 14 
Classification issues ............................................................................................................... 15 
Potential reasons for increased rates of deficiency and insufficiency ................................... 16 
Appropriate marker of maternal vitamin D level ...................................................................... 17 
Sources of variation in maternal vitamin D levels .................................................................... 18 
Variability in maternal vitamin D due to location ................................................................. 18 
Variability due to pregnancy ................................................................................................. 19 
Maternal vitamin D status related to fetal growth ..................................................................... 19 
Maternal vitamin D status related to offspring size at birth ...................................................... 20 
Maternal vitamin D status and infant birth weight ................................................................ 20 
Maternal vitamin D and infant body composition ................................................................. 21 
Conclusion ................................................................................................................................. 21 
 
vii 
Chapter III: Methods ..................................................................................................................... 22 
Study Overview ......................................................................................................................... 22 
Sample ....................................................................................................................................... 22 
Inclusion/Exclusion Criteria ...................................................................................................... 22 
Setting........................................................................................................................................ 23 
Ethics ......................................................................................................................................... 23 
Procedures ................................................................................................................................. 24 
Instrumentation: ........................................................................................................................ 24 
Fetal biometrics by 2D ultrasound ......................................................................................... 24 
Infant body composition by air displacement plethysmography (Pea Pod
©
) ........................ 25 
Maternal serum 25-hydroxyvitamin D .................................................................................. 26 
Statistical Analysis .................................................................................................................... 26 
Chapter IV: Results ....................................................................................................................... 28 
Study Characteristics for Body Composition Assessment ........................................................ 28 
Correlation matrix of variables of interest ................................................................................ 32 
Predictors of Infant Birth Weight .............................................................................................. 32 
Predictors of Infant Body Composition .................................................................................... 33 
Percent fat .............................................................................................................................. 33 
Fat Mass ................................................................................................................................. 33 
Study Characteristics for Estimated Fetal Weight Assessment ................................................ 34 
Predictors of Estimated Fetal Weight........................................................................................ 38 
Chapter V: Discussion .................................................................................................................. 39 
Birth Weight and Body Composition and Serum Vitamin D.................................................... 39 
Infant birth weight ................................................................................................................. 39 
Infant body composition ........................................................................................................ 40 
Estimated Fetal Weight and Serum Vitamin D ......................................................................... 41 
Limitations and Strengths.......................................................................................................... 42 
Conclusions ............................................................................................................................... 42 
Appendix ....................................................................................................................................... 51 
 
1 
Chapter I  
INTRODUCTION 
Vitamin D has long been recognized to play a role in bone modeling, but as of late, the 
potential role vitamin D may play in various metabolic conditions has been presented (1). A 
population of particular interest in the emerging vitamin D story is pregnant women. The 
Institute of Medicine’s (IOM) Recommended Dietary Allowance (RDA) for vitamin D in 
pregnancy rose from 200 IU per day to 600 IU per day in 2010 (2). Although this rise triples the 
previous recommendation many believe that it is still not enough (3, 4). According to the 2009 
NHANES data, 28% of pregnant women had a serum 25-dihydroxy vitamin D (25(OH)D) level 
less than 50nmol/L. This level is classified as “at risk for vitamin D inadequacy” by the IOM. 
Furthermore, seven percent of pregnant women had serum levels <30nmol/L which is classified 
as “at risk for vitamin D deficiency” (5).  
Disagreement exists as to the desired amount of vitamin D intake that is required to 
achieve optimal serum levels. The Endocrine Society suggests that an intake of 1500-2000 IU/d 
may be required to achieve optimal serum 25(OH)D in pregnancy (3). However, Hollis et al 
suggests that in pregnancy optimal serum 25(OH)D levels are much higher and require an intake 
of 4000 IU to be achieved (4).   
Adequate vitamin D intake is important in pregnancy due to possible associations 
between maternal vitamin D status and fetal and infant outcomes. Maternal vitamin D 
insufficiency or deficiency has been related to increased risk of gestational diabetes (6) and pre-
eclampsia (7) in the mother. In the fetus, maternal vitamin D insufficiency or deficiency has been 
related to growth restriction and an increase in adiposity during childhood (8). Few studies have 
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reported these findings and reports are contradictory (9-19). Therefore, the purpose of this thesis 
is to investigate the relationship between maternal serum 25(OH)D levels and fetal growth and 
neonate body composition (percentage body fat (%fat), fat mass (FM) and fat-free mass (FFM)). 
 
Statement of Purpose 
The purpose is to investigate the relationship between maternal serum 25(OH)D levels and fetal 
growth and neonate body composition. 
 
Research Question 
Is maternal serum 25(OH)D measured late in pregnancy related to fetal growth and neonate body 
composition at birth? 
  
Specific aims and Hypotheses 
Aim 1: Examine the relationship between maternal serum 25(OH)D levels measured late in 
pregnancy and fetal growth. 
Hypothesis 1.1: Maternal serum 25(OH)D late in pregnancy is positively related to 
estimated fetal weight (EFW) by ultrasound in early and late pregnancy 
Hypothesis 1.2: Maternal serum 25(OH)D late in pregnancy is positively related to infant 
birth weight 
Aim 2: Examine the relationship between maternal serum 25(OH)D levels measured late in 
pregnancy and neonate body composition (%fat, FM and FFM). 
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Hypothesis 2.1: Maternal serum 25(OH)D is positively related to neonate %fat within 72 
hours of birth 
Hypothesis 2.2: Maternal serum 25(OH)D is positively related to neonate FM within 72 
hours of birth  
 
Special Note 
In order to report variables in similar units, conversions from mircograms (µg) to international 
units (IU) and nanograms (ng) to nanomol (nmol) were completed with the follow conversion 
factors:  
1microg= 40 IU 
1ng= 2.5 nmol/L 
These conversions are recognized and used by the IOM (20).
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Chapter II 
LITERATURE REVIEW 
Vitamin D: The sunshine vitamin  
Vitamin D is a unique vitamin because unlike others it can be obtained from food as well 
as synthesized from sunlight. It also contains hormone-like traits in its function and seco-steroid 
structure (1). The metabolic pathways for synthesis, transport and regulation and details of the 
vitamin D receptor will be discussed. Lastly, food sources of vitamin D are included. Also, for 
consistence all serum 25(OH)D levels are reported in nmol/L. A conversion factor of 2.5nmo/l 
per ng/L was used (2). Similarly, intake of vitamin D is expressed in IU with 1 microgram 
equaling 40IU (2). 
 
Metabolic pathway for synthesis 
 Ultraviolet (UV) B rays with a length of ~285-320 nm can convert 7-dehydrocholesterol 
found in the skin to previtamin D3 (1). Activation of 7-dehydrocholesterol by UV B rays varies 
by the amount of skin exposed (21), latitude (22), season, time of day, cloud cover (23), the use 
of sunscreen (24) and melanin within the skin (22). After 2 to 3 days, the unstable double bonds 
within previtamin D3 are rearranged to form vitamin D3, also known as cholecalciferol (1).  
Cholecalciferol within the skin diffuses into the blood bound to vitamin D binding 
protein. Vitamin D binding protein transports most of the cholecalciferol to the liver; however 
some may go to other tissues such as muscle and adipose (1). Dietary Vitamin D (ergocalciferol 
and cholecalciferol) is absorbed within the duodenum and distal small intestine (1). Diffusion 
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into the enterocyte is done via micelle formation. This requires the presence of bile acids and 
pancreatic lipase within the intestine. The presence of fat increases excretion of bile acids and 
pancreatic lipase, thus its presence in the intestine increases the efficacy of vitamin D absorption 
(2).  Dietary vitamin D transports through the body within chylomicrons, and may be released 
into other tissues during hydrolysis of the chylomicron by lipoprotein lipase (2). Vitamin D from 
either the diet or from the skin does not remain in the circulation very long due to uptake by 
adipose tissue or the liver. This generally occurs within hours of absorption (25).  
 Once vitamin D3 is in circulation, it must be activated by a two-step process.  The first 
step occurs in the liver where vitamin D3 is hydroxylated by 25-hydroxylase to form calcidiol 
(also known as 25-hydroxy vitamin D (25(OH)D)). In the second step, 25(OH)D reaches the 
kidney and is hydroxylated again by 1 α-hydroxylase forming calcitriol, also known as 1,25-
dihydroxy vitamin D, the active form of vitamin D (1). Serum 25(OH)D is used to assess vitamin 
D adequacy. This is due to the short half-life of  calcitriol of about 4 to 6 hours (25), its 
regulation by other hormones such as parathyroid hormone (PTH) and lack of direct association 
with vitamin D intake and skin synthesis (2). The half-life of serum 25(OH)D is several weeks 
and therefore a more stable measure of vitamin D status (25). The main storage site for 
25(OH)D3 is thought to be the blood and muscles, while adipose and skin store vitamin D in the 
form of cholecalciferol (1).  
 
Regulation of Vitamin D synthesis 
 Vitamin D concentrations within the body are regulated by various pathways such as 
formation and activation. The conversion of 7-dehydrocholesterol and previtamin D3 to other 
metabolites helps to prevent toxicity when exposed to UV B rays for extended periods of time. 
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The formation of previtamin D3 from7-dehydrocholesterol plateaus once 10-15% of the supply is 
converted (22). At this point UV rays begin to convert excess 7-dehydrocholesterol to lumisterol, 
and excess previtamin D3 to tachysterol. Vitamin D binding protein has little affinity for these 
two compounds and they are often sloughed off with skin cells (1, 22). Absorption of vitamin D 
within the intestines is not regulated. This is why large doses of synthesized vitamin D can cause 
symptoms of toxicity (2). 
 Vitamin D concentration is also controlled by the 2 steps required for activation. The first 
hydroxylation forming 25(OH)D within the liver is not tightly regulated (1, 26). Although it has 
been observed that NADPH-dependent 25-hydroxylase is more efficient when circulating levels 
of cholecalciferol are limited (1). Hydroxylation of cholecalciferol occurs primarily in the liver, 
however some occurs within the intestine and kidney (26). Final hydroxylation at position 1 of 
25(OH)D is more tightly regulated by 1-hydroxylase. This enzyme is stimulated by the increased 
presence of PTH via a cAMP/phosphatidylinositol 4,5-biphosphate (PIP2)-medicated signal 
transduction mechanism (26). Also, decreased plasma calcium increases 1-hydroxylase. The 
activation of 1-hydroxylase by plasma PTH and calcium levels is crucial to calcium homeostasis 
within the body (1). Over production of 1,25 (OH) D3 is prevented via feedback regulation where 
an increased concentration of the product  1,25(OH)D3 decreases activity of 25-hydroxylase (26). 
Finally, activated vitamin D is formed to increase serum phosphorus. A lower phosphorus intake 
stimulates serum 1,25(OH)D3, which then increases resorption of phosphorus from bone (1).  
 
Vitamin D receptor 
In order for vitamin D to elicit a physiological effect, it must first gain access to the cell 
through the vitamin D receptor (VDR). The VDR is member of a superfamily of nuclear 
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receptors that includes sex and adrenal steroids (27). Superfamily receptors are 
compartmentalized into the amino-acid domain at the NH2 terminus, DNA-binding domain and 
ligand binding domain at the COOH terminal (26-28). In the ligand domain, calcitriol binds to 
VDR and is phosphorylated and then binds with retinoid X or retinoic acid receptors (1, 26, 27, 
29). This causes an allosteric change in the receptor making it able to bind with vitamin D 
response elements within target genes (1, 27). Zinc fingers, located in the DNA-binding domain 
(26), interact with hexonucleotide sequences in the vitamin D response element (29) causing it to 
enhance or inhibit transcription of genes which code for specific proteins (1, 26). The primary 
known proteins that results from VDR interaction with genes include osteocalcin, 24 
hydroxylase, and calbindin (1).    
 VDR presence in multiple tissues not related to calcium homeostasis raised questions that 
it may play a role in other mechanisms of the body. Receptors have been found in organs such as 
the lung, muscle, skin, and placenta (1, 30). Furthermore, Ramagopalan et al found 229 genes 
that had a significant change in expression in response to vitamin D (31).  
 
Food sources of vitamin D 
 Dietary vitamin D is available in two forms, D3 and D2. Vitamin D3 is synthesized in 
human skin and found naturally in the diet from some animal sources (2).  Relatively few foods 
are a natural source of vitamin D. Fatty fish such as swordfish, salmon, and tuna have the highest 
IU of vitamin D per serving ranging from 137-566 IU. This is followed by beef liver and egg 
yolk which have about 41 IU (32). Many foods are fortified with either a man-made form or 
plant derived form of vitamin D, vitamin D2, known as ergocalciferol.  
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Although it is not required for milk to be fortified with vitamin D2, in the United States, 
most manufacturers fortify milk with 100 IU vitamin D2 per cup (2). Other fortified sources of 
vitamin D include, orange juice and ready-to-eat breakfast cereals (32).  Hill et al in 2012 
discovered that 44% of the American and Canadian intake of vitamin D comes from fortified 
milk products (33). Since vitamin D3 and D2 undergo the same two step activation process to 
form calcitriol and have similar abilities to cure vitamin D deficiency rickets, they are considered 
equivalent (26).  
 
Vitamin D’s role in health 
 Vitamin D is known to play a role in calcium uptake and therefore bone health in children 
(rickets) and adults (osteomalacia) (2). Research has also identified additional roles vitamin D 
may play in other conditions including inflammation (34), cardiovascular disease (29, 34-39) and 
type 2 diabetes (40-48). These conditions and their relationship to vitamin D are discussed 
below.  
 
Bone health 
Vitamin D’s role in calcium homeostasis and bone modeling is well understood (1). 
When serum calcium decreases, the parathyroid gland releases PTH. A rise in PTH stimulates 
the kidneys to produce the active form of vitamin D, calcitriol. Calcitriol then increases intestinal 
absorption of calcium by activating VDRs in the intestinal mucosal cells. Receptor activation in 
these cells stimulates the production of calbindin, a calcium transport protein, which increases 
enterocyte absorption of calcium from intestine (1).  Calcitriol and PTH stimulate the maturation 
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of osteoclasts in the bone, a cell which catabolizes the bone matrix releasing calcium and 
phosphorus in the blood stream, thus increasing serum calcium levels. Furthermore, calcitriol 
aids in the remodeling of the bone matrix. As serum calcium and calcitriol increase, there is a 
decrease in PTH, thus decreasing maturation of osteoclast cells which break down bone (2).  
 
Inflammation 
 The discovery of vitamin D receptors in various tissues has sparked the investigation of 
vitamin D’s role in other aspects of health. Calcitriol has been studied for its ability to decrease 
inflammation via various pathways, one being the inhibition of (cyclooxygenase) COX-2 (34). 
Tumor growth is facilitated by the COX-2 enzyme production of prostaglandins. In human 
prostate cancer cells, Moreno et al discovered that calcitriol has the ability to decrease 
expression of COX-2 enzymes and decrease the ability of prostaglandins to facilitate tumor 
growth (34).  
 
Cardiovascular disease 
Sufficient serum 25(OH)D has been associated with decreased risk of cardiovascular 
disease (29). A large scale observational study using NHANES data found that when adjusting 
for other confounders, those with the lowest serum 25(OH)D had a 40% increase in risk of 
cardiovascular mortality (36). Moreno et al’s review of observational studies agrees there is an 
increased risk of cardiovascular disease at serum 25(OH)D concentrations less than 37.5 nmol/L 
(34). A meta-analysis of randomized-control trials by Witham et al saw a significant decrease in 
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diastolic blood pressure among those supplemented with vitamin D. This association was only 
seen in those whose baseline blood pressure was elevated (38).  
Vitamin D may affect cardiovascular health via the renin-angiotensin-aldosterone system 
and parathyroid hormone (1, 37).  The rate limiting step of the renin-angiotensin-aldosterone 
system is the formation of renin (39). Using knockout mice, Yuan et al concluded that calcitriol 
attached to VDR blocked the binding of proteins that stimulate the production of renin (39). Thus 
vitamin D prevents the initiation of the blood pressure raising system. Calcitriol also decreases 
expression of parathyroid hormone, by blocking transcription of pre-parathyroid hormone within 
parathyroid tissue (1). Explanation of the relationship between elevated parathyroid hormone and 
hypertension has not been established, although positive associations have been observed (35). 
 
Type 2 Diabetes 
The presence of VDR within pancreatic β-cells and localized production of calcitriol 
suggest that insufficient vitamin D may affect risk of type 2 diabetes (41). A long term, large 
scale observational study by Pittas et al found that women who consumed > 800 IU of vitamin D 
per day had a 23% lower risk of developing type 2 diabetes (45). Furthermore, a recent meta-
analysis of observational studies agreed that there was an inverse relationship between serum 
25(OH)D and risk for diabetes or metabolic syndrome (42). Direct effect of vitamin D 
supplementation on insulin sensitivity and secretion is difficult to assess due to its association 
with decreasing overall weight and FM (46-48).   However, after adjusting for race, BMI and 
age, vitamin D supplementation of 2,000 IU/day in a pre-diabetic population was associated with 
increased insulin secretion and slower increase in HbA1C (43). Nikooyeh et al found similar 
results when comparing the same supplementation amount in diabetics, after adjusting for FM. In 
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this study, there was no association between serum 25(OH)D and any glycemic markers after 
adjusting for confounding variables (44).  
The mechanism by which vitamin D may affect insulin sensitivity is not well understood. 
It has been suggested that is serum 25(OH)D is negatively correlated to β-cell secretion and 
positively correlated to insulin sensitivity (1). However, others propose that it indirectly effects 
glycemic control via regulation of inflammation. Bock et al supplemented healthy subjects with 
140,00 IU per month and discovered that it caused an increase in the percentage of regulatory T 
cells, but did not affect β-cell function (40). 
 
Vitamin D and maternal health during pregnancy 
 In addition to the health effects in a non-pregnant state, growing evidence suggests a role 
for an effect of vitamin D deficiency during pregnancy. Pregnancy results in an increased risk of 
vitamin D insufficiency due to the increased demand for calcium to support fetal bone deposition 
(7). Current research suggests vitamin D deficiency is related to the development of gestational 
diabetes (49-53) and pre-eclampsia (54). Assessment of vitamin D sufficiency for mom and the 
baby in pregnancy is best measured by 25(OH)D as this is the form that crosses the placenta. 
Calcitriol is formed from 25(OH)D within the fetal kidney (12). 
 
Gestational diabetes  
 Many risk factors associated with gestational diabetes are non-modifiable: first degree 
relative with diabetes, history of glucose intolerance, increased maternal age and previous infant 
with macrosomia (55). Obesity is another risk of gestational diabetes (55) but not one that can be 
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safely modified during gestation (56). Impaired glucose tolerance in pregnancy increases glucose 
availability within the infant causing baby to increase production of insulin to control blood 
glucose (55). This can result in babies that are born large. Twenty percent of babies born to 
mothers with gestational diabetes are macrosomic, compared to 12% of babies born to mothers 
without gestational diabetes (57). Furthermore, the offspring of mother with gestational diabetes 
have a significantly higher risk of developing type 2 diabetes later in life (50, 51).  
 Like type 2 diabetes, vitamin D status may affect severity/incidence of gestational 
diabetes (6, 40-45, 49, 52, 53).  Zhang et al observed that the risk of gestational diabetes 
increased 2.66 fold in participants that had serum 25(OH)D levels <50nmol/L. Serum 25(OH)D 
and glucose levels after a glucose tolerance test were inversely correlated (6, 52).  
 Causes for the correlation of vitamin D deficiency and gestational diabetes are unknown. 
Using the homeostasis model assessment index to assess insulin resistance, Maghbooli et al 
found that vitamin D deficient women have 43% higher insulin insensitivity (52). Intervention 
studies need to be conducted to provide more insight into the relationship. A large scale 
European intervention currently underway  aims to assess the impact of healthy eating, physical 
activity and vitamin D supplementation on pregnancy outcomes (58).  
 
Pre-eclampsia 
 Vitamin D’s association with cardiovascular health in pregnancy is seen in pre-eclampsia. 
A prospective cohort study of 697 pregnant women, found that a serum 25(OH)D levels less than 
50nmol/L at 24-26 weeks gestation were significantly associated with an increased risk of 
developing pre-eclampsia. No association was seen in early pregnancy (54). Few studies have a 
primary aim to assess pre-eclampsia. The mechanism for this association is thought to be due to 
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poor regulation of calcium within the blood or possibly interactions between vitamin D, rennin 
and PTH production (35, 39).  
 
Maternal obesity and vitamin D deficiency 
In the United States 47.5% of women who are of childbearing age are overweight or 
obese (59). Studies have consistently found that those who are obese have an increased risk of 
vitamin D deficiency (46-48). No definite explanation has been determined however there are 
two theories, the sequestration of vitamin D by adipose and the regulation of adipose tissue by 
vitamin D (46).  Wortsman et al did an intervention where non-pregnant obese and lean 
participants had serum 25(OH)D drawn 24 hours after they were either exposed to UV radiation 
or given a 50,000 IU dose of Vitamin D3. The study found that BMI was inversely correlated 
with serum vitamin D3 after exposure to equal amounts of UV light. Since subcutaneous fat 
stores vitamin D3, it is thought that more vitamin D was sequestered in the obese than the non-
obese subject due to increased FM (48). The second hypothesis suggests that vitamin D regulates 
adipose tissue. This theory is more difficult to explore in human studies. A recent 12 week, 
double-blind, randomized, controlled trial in non-pregnant adults discovered that daily 
supplementation with 1000 IU of vitamin D was significantly associated with a decrease in body 
FM when compared to placebo. There were no associations between body weight or waist 
circumference. It is hypothesized that the mechanism is related to regulation of PTH and 
intracellular calcium concentration. The thought is that when vitamin D is increased, de novo 
lipogenesis is increased as well (47).  
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Recommendations for vitamin D intake during pregnancy 
Vitamin D’s role in disease states has become popular in scientific research. This has led 
to a need for standardization of recommendations and classification of status for the general 
population and for pregnant women. Debate has arisen as to what should be considered when 
determining these recommendations for pregnancy. The IOM defines adequacy as a serum level 
of 25(OH)D >50nmol/L (2). It is estimated that an intake of 600 IU/d of vitamin D is needed to 
obtain this level (2). The Endocrine Society defines adequate serum 25(OH)D as that >75nmol/L 
and estimates that a much greater intake of 1500 IU-2000 IU/d of vitamin D is needed to reach 
this blood level (3). (See Table 1 for IOM and Endocrine Society Classifications) 
 
 
 Rates of insufficiency or deficiency during pregnancy  
Using data from the 2001-2006 NHANES survey, Ginde et al analyzed prevalence of 
inadequate serum 25(OH)D using both IOM and Endocrine Society criteria. Thirty-three percent 
of pregnant women had serum 25(OH)D levels <50nmol/L, considered less than adequate by the 
IOM. Sixty-nine percent had serum levels <75nmol/L, the amount considered inadequate by the 
Endocrine Society. Percentages of those women who were inadequate decreased as trimester 
increased. This is thought to be related to the increased duration of supplementation which also 
led to a positive association with the amount of women with adequate serum levels (60). In 
TABLE 1 
Recommended serum 25(OH)D in pregnancy and daily vitamin D intake to achieve those levels  
 Serum 25(OH)D Intake Upper limit 
Institute of Medicine  >50 nmol/L 600 IU 4,000 IU 
Endocrine Society >75 nmol/L 1,500-2,000 IU 10,000 IU 
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another dataset from the United States, mean serum levels for pregnant and non-pregnant women 
were 65nmol/L and 59nmol/L respectively with 42% of non-pregnant women having inadequate 
serum 25(OH)D. Throughout the data, a larger percent of non-pregnant women had serum 
25(OH)D levels lower than pregnant women (60). This is hypothesized to be due to the increased 
use of vitamin D supplementation found in prenatal vitamins.  
Across the globe, many studies have found large portions of pregnant women with low 
serum 25(OH)D.  Of the women participating in England’s South Hampton Women’s Survey, 
33% had serum 25(OH) levels <50nmol/L, and 63% were <75nmol/L (8). In India, 66% of the 
559 participants had serum levels <66%nmol/L (61). However, a study of 125 Gambian women 
did not contain any women <50nmol/L, and only 11% <80nmol/L (19).  
Trends of deficiency continue in non-pregnant women and men. Countries close to the 
equator that receive ample sunlight, such as those in the middle east, have a large portions of 
women who are vitamin D deficient (62). In a sample of healthy Asian Indians 78% were 
considered inadequate by IOM standards (63). Even across Australia 40-67% of individuals are 
estimated to have serum levels <25nmol/L (64). 
 
Classification issues 
 As shown in Table 1, each society presents different levels for classification of deficient, 
insufficient, sufficient and possible adverse effects. The IOM (who set official RDA) bases  
recommendations on research pertaining only to what is needed for adequate bone health and 
does not consider the extra-skeletal effects of vitamin D (2). The Endocrine Society includes 
research that addresses other adverse outcomes associated with decreased serum 25(OH)D such 
as increased risk for pre-eclampsia and cesarean section (2, 3). The main focus of the debate 
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whether the information on extra skeletal effects of vitamin D is strong enough to change 
recommendations. This results in recommendations that are quite different due to each society 
having aims that are intended to address different outcomes. Further complicating the vitamin D 
story are different recommendations being suggested by researchers. Hollis et al defines a 
vitamin D serum level between 100-150 nmol/L to be ideal. According to his research, this 
requires an intake of 4000 IU/d of vitamin D to achieve sufficiency (4).  
Among the articles reviewed in regard to vitamin D and pregnancy outcomes, there was 
inconsistent classification of vitamin D intake and serum status. Only one study done in 2006 
used a cut off for adequacy that is less than the current IOM recommendations. Ruth Morley et al 
defined serum levels <28nmol/L to be deficient, while Gale et al and Leffelaar et al used current 
IOM recommendations (13, 18, 61). More recent studies done in 2011, and 2012 used the 
Endocrine Society’s classification serum adequacy or even higher (10, 15, 16, 19). 
 
Potential reasons for increased rates of deficiency and insufficiency 
It is possible that changes in lifestyle and eating habits may be why vitamin D deficiency 
has increased. The amount of skin exposed has been significantly associated with serum 
25(OH)D levels (21, 65). Perampalam et al studied  pregnant women and found that as the 
amount of skin exposed to the sun increased, so did the average 25(OH)D (65). This trend was 
also seen in an analysis of the 2003-2006 NHANES data in which lower levels of 25(OH)D were 
found in those who wore hats, long sleeves and stayed in the shade on sunny days (21). Another 
concern is the use of sunscreen, which may block UVB exposure and synthesis of vitamin D 
(66). Many studies that assess the effect of sunscreen on vitamin D status are conflicting. Some 
randomized controlled trials found decreased serum levels with sunscreen use. However, based 
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on observational data, the manner in which the public uses sunscreen is not associated with 
deficiency (24).  
Eating habits may also contribute to decrease vitamin D. According to NHANES data 
from 1999-2004, milk provided 44% of Americans vitamin D intake. Unfortunately milk intake 
is on the decline (33). The percentage of individuals in all age groups who drink milk has 
significantly decreased from 1977-1978 to 2005-2006 (67). Historical vitamin D intake is limited 
because vitamin D intake was not included in NHANES What We Eat in America data tables 
until 2007 (68). The Minnesota Heart Survey, however, has collected information on vitamin D 
intake back to 1980.  In 1980-1982, the average intake was 197.6 IU while in 2007-2009 this 
dropped significantly to 174 IU (69). Recent NHANES data reveals that although vitamin D 
intake from food is not exactly as it was in the 1980s, intake of supplements has increased from 
33% in 2007-2008 to 36% in 2009-2010 (68, 70).  
  
Appropriate marker of maternal vitamin D level 
The serum measurement of 25(OH)D is ideal in this type of research because it is the 
form of vitamin D that is passed from mother to fetus (23). Also 25(OH)D is measured instead of 
the active form of vitamin D calcitriol, because it is not effected by vitamin D intake and it has a 
very short half-life (1). Two methods are used to assess serum 25(OH)D, liquid chromatography 
and antibody based (71). Liquid chromatography is sensitive, specific and reproducible and is 
considered the “gold standard” for analysis. It has the ability to differentiate between 25(OH)D3 
and 25(OH)D2. This is further supported by the production of a calibration solution to assess 
accuracy of measures (71). Antibody based analysis only detects total 25(OH)D. This assay is 
more commercial and is the most common in literature (2).  
 
18 
Of antibody analyses, two are most common, enzyme-linked immunosorbent assay 
(ELISIA) and Radioimmunoassay (RIA). ELISA has a 23% cross-reactivity for 25(OH)D and 
radioimmunoassay has a 75% cross-reactivity for 25(OH)D (72). Due to these different assay 
measures, method of serum analysis should be considered when evaluating research.   
 
Relationship between serum measured vitamin D and vitamin D from dietary assessments 
 Both the IOM and Endocrine Society agree that dietary intake of vitamin D has the 
ability to effect serum levels (2, 3). A dose response reaction is undecided. Although many 
studies have evaluated supplementation and intake, many factors influence vitamin D status that 
an increase in 1 nmol/L has not been associated with a supplemental amount of vitamin D. 
However, multiple studies have found and positive association between serum 25(OH)D and 
intake from food or supplemental vitamin D (13, 15, 73, 74). 
 
Sources of variation in maternal vitamin D levels  
Variability in maternal vitamin D due to location 
 The amount of UVB rays available to the skin effects its ability to synthesize previtamin 
D3 (1). As latitude increases, the angle at which the sun hits the earth decreases and the amount 
of UVB photons available decreases, which leads to decreased synthesis of Vitamin D3 in the 
skin (75). Due to rotation of the earth, this angle changes seasonal as well. Webb et al observed 
that skin exposed to direct sunlight in Boston, Massachusetts, 42.2 degree north, produced no 
pre-vitamin D3 between the months of November and February. While further south at 34 and 18 
degrees North, the skin produced previtamin D3 year round (76).  
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Variability due to pregnancy 
 The effect of pregnancy on 25(OH)D is hard to determine due to increased use of 
supplements during gestation. According to 2001-2006 NHANES data 73% of women who were 
pregnant, were taking a supplement with vitamin D, compared to 32% of non-pregnant women 
(60). Furthermore, an observational study compared 25(OH)D of pregnant and non-pregnant 
women found that levels rose and fell in similarly in association with season of measurement 
(17). NHANES data however found that 25(OH)D tended to increase with GA. The mean 
25(OH)D levels for the first, second and third trimesters were 55 nmol/L, 62 nmol/L and 80 
nmol/L, respectively. The increase across trimesters could be related to increased use of vitamin 
D supplementation across the pregnancy (60).  
 
Maternal vitamin D status related to fetal growth 
Within the articles reviewed, serum measurements were taken throughout all stages of 
pregnancy (9-19). When first trimester serum measures were taken, an association was found 
between small-for-gestational age and serum measures in 2 of 3 studies. Hossain et al found a 
positive correlation between maternal serum status and fetal cord blood. Furthermore there was 
an inverse relationship between cord blood serum 25(OH)D and birth weight (16). It is possible 
that serum measures throughout gestation are inconsistently correlated to fetal growth. The 
growth trajectory of the infant is determined in the early stages of pregnancy so measurements at 
this time should be studied closely (61). No articles were found that compared estimated fetal 
growth to serum 25(OH) measures within stages of pregnancy. Measurement of EFW would be 
beneficial to understanding how serum measures effect fetal growth trajectory throughout 
pregnancy. 
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Maternal vitamin D status related to offspring size at birth 
Maternal vitamin D status and infant birth weight 
 The data regarding the effect of 25(OH)D on low birth weight is difficult to analyze due 
to varied GA at measure of 25(OH)D, range of measures accessed and methods of analyzing 
weight. Large observational studies with more than 1000 multi-ethnic participants found positive 
associations with 25(OH)D measures at less than 28 weeks gestation and infant birth weight (10, 
11, 14, 61). Small observational studies found no association in early gestational measurements 
(17-19, 77).  When 25(OH)D was taken at greater than 28 weeks gestation or at birth, no 
association was found (12-14, 17, 19). 
 The presence of participants with low serum levels also effected outcomes. Studies 
containing most if not all participants above 30nmol/L tended to see no association, while those 
with ranges that went below 30nmol/L saw a positive correlation (9, 10, 14-17, 19, 61). This may 
be explained by one study that found the lowest risk for having an infant that is small for GA at 
serum levels between 60 and 80nmol/L (10).  
 Studies that measure small for GA rather than birth weight were more likely to find 
correlations between serum measures and birth outcomes. An infant that is small-for-gestational 
age if they are lower than the 10
th
 percentile (78). Small-for-gestational age is a beneficial 
measure because fetal weight can vary greatly across sexes and gestational periods. It allows for 
researchers to ensure that they are comparing infants to their peers. Within the articles, Bodnar et 
al found the lowest risk for small-for-gestational age in mothers that had serum levels between 
60nmol/L and 80nmol/L in early gestation. Also, in a study by Lefelaar et al, women categorized 
as having adequate serum levels (>50nmol/L) had a significantly lower percentage of small-for-
gestational age infants than those found in the deficient range (<29.9nmol/L) (10, 61).  
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Maternal vitamin D and infant body composition 
 As explained above, obesity is associated with low 25 (OH) D and it could be explained 
by FM. Maternal vitamin D concentrations may also have an effect on infant body composition. 
Crozier et al discovered that infants born to mothers who had 25 (OH) D concentrations 
>75nmol/L had infants with 10% greater FM than those with <50nmo/L (8). Associations with 
maternal vitamin D intake during pregnancy, and increased FM at 6 and 9 years old has been 
identified (8, 13). 
Conclusion 
  The variation among research methods makes it difficult to determine if there is an exact 
correlation between maternal serum 25(OH)D and infant birth outcomes. As more research is 
done, professionals must consider ways to avoid pitfalls that may invoke bias or limit clarity of 
their research. An ideal project should involve limitations on classification of serum 25(OH)D to 
avoid bias based on classification.  It should consider multiple fetal growth measures such as 
small-for-gestational age, birth weight, EFW through gestation and infant body composition and 
compare these to maternal serum measures that have been taken at multiple times throughout 
pregnancy.  
 The prevalence and severity of low birth weight infants is the reason why more 
standardized research needs to be performed. It is only then institutions like the IOM and 
Endocrine Society will be able to confidently decide on an ideal vitamin D intake to recommend 
to mothers so that they may have a health pregnancy.  
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Chapter III 
METHODS 
Study Overview 
 This study used the cohort from multiple Pregnancy Health Studies being conducted at 
the University of Kansas Medical Center. The purpose of this study is to explore the relationship 
between maternal serum 25(OH)D measured late in pregnancy, fetal growth and neonate body 
composition at birth. 
 
Sample 
 Women that were included were participants in three clinical research studies (Factors 
affecting growth patterns and body composition of infants study (HSC# 13126), Maternal 
cardiometabolic health during pregnancy study (HSC# 13309), and Characterization of adiposity 
in pregnancy and its relationship to immunity and infant body composition (HSC#12793)) being 
performed at the University of Kansas Medical Center in Kansas City, Kansas. Only singleton 
healthy pregnancies were included in this study. Participants were recruited from the OB clinics 
at the KU Hospital.  
 
Inclusion/Exclusion Criteria 
 Women were included in the study if they were: 
1. between the ages of 18 and 45 years old 
2. singleton pregnancy 
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3. English speaking 
 Women were excluded from the study if they: 
1. were underweight according to their pre-pregnancy BMI 
2. were under the age of 18 years old or over 45 years old 
3. had known infectious diseases, diabetes mellitus, hypertension, use tobacco 
products or any drugs during pregnancy 
4. did not speak English 
5. were carrying more than one fetus 
 
Setting 
 This study was conducted at the University of Kansas Medical Center March 2012 to 
August 2013.  
 
Ethics 
This study was approved under the existing protocol of the Factors affecting growth 
patterns and body composition of infants study (HSC# 13126), Maternal cardiometabolic health 
during pregnancy study (HSC# 13309) and Characterization of adiposity in pregnancy and its 
relationship to immunity and infant body composition (HSC#12793) protocols which were 
assessed and approved by IRB.  Before participation, all subjects read through the consent form 
with a study coordinator who was available to answer any questions. If participant chose to 
participate, they were enrolled after signing the consent form. Once enrolled, participants were 
assigned a number, which will be used to safely identify their records and maintain anonymity.   
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Procedures 
 Participants attended a study visit at 34-38 weeks. Baseline and descriptive data were 
collected at the visit. This includes patient reported pre-pregnancy weight and parity. The visit 
included a blood draw by a registered nurse. Infant birth weight, GA at birth, and maternal 
weight at delivery were obtained from the patient’s electronic medical chart. 
 
Instrumentation: 
Fetal biometrics by 2D ultrasound 
Fetal biometrics by 2D ultrasound and the Hadlock equation were used to estimate fetal 
weight at the study visit. The Hadlock equation requires measurements of 3 anatomical locations: 
head circumference, abdominal circumference, and femur length (79). Images from which 
measurements are taken should contain specific anatomical locations to ensure accuracy across 
screening (2). The image of the head used for biparietal diameter and head circumference should 
be oval shaped and contain the thalami, third ventricle, and septum pellucidum (80, 81). An 
image that is round or contains the brainstem or cerebellum will not produce accurate 
measurements (80). Biparietal diameter is measured from the outer edge of the proximal skull to 
the inner edge of the distal skull (80). Head circumference is measured around the outer 
perimeter of the skull (Figure 1 A) (80). Abdominal circumference images are a rounded 
transverse picture that should contain the spine to the right or left (3 or 9 o’clock) of the image, 
the stomach on the left side of the fetal abdomen, symmetrical ribs and the junction of the left 
and right portal vein (80, 81). Circumference should be measured at the skin’s surface (80). 
(Figure 1 B). Finally, images of the femur should be taken with the length of the bone visible and 
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perpendicular to the transducer (81). Measurement is taken along the length of the bone with 
assurance as to not include the distal epiphysis (Figure 1C) (80). 
 
  
 Figure 1 A-C 
A. Image of fetal head, biparietal diameter represented by 
solid line, and circumference represented by dashed 
line. The cavum septum pellucidum is indicated (CSP) 
B. Image for measurement of fetal abdomen 
circumference. An arrow indicates the junction of the 
umbilical vein and portal sinus. The spine is located on 
the right and the stomach is the dark portion at the 
bottom of the image.  
C. Image of the fetal femur indicating a proper 
measurement along the length of the bone. 
Images obtained from Obstetrics: Normal and Problem 
Pregnancies, 6
th
 ed. ©
 
2012 (80)  
 
Infant body composition by air displacement plethysmography (Pea Pod
©
) 
 Infant FM, FFM and %fat were measured within 72 hours of life using the Pea Pod
©
 
(Life Measurement Inc. Concord, CA).  Density measurement via air-displacement 
plethysmography is a fast, easy, and non-invasive procedure (82). The Pea Pod
© assesses body 
composition using densitometry, where body density is determined by dividing body mass by 
A 
A B 
C 
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body volume. In this method thoracic gas volume is predicted in infants because measuring it is 
not feasible (82). The Pea Pod
© 
is an accurate measure of infant body composition, Sainz et al 
validated the Pea Pod
© 
against chemical analysis using 24 bovine tissue phantoms (83). The Pea 
Pod
© 
has also been successfully validated using a 4-compartment model in 49 healthy infants by 
Ellis et al (84). 
 
Maternal serum 25-hydroxyvitamin D 
Four tablespoons of blood were taken by a trained registered nurse. This blood was 
separated within 24 hours of blood draw and stored in -80 degree freezer until time of batch 
analysis. Plasma was analyzed for serum 25-hydroxy vitamin D content using enzyme-linked 
immunosorbant assay (ELISA). Included in the batch analysis of serum 25(OH)D is a calibration 
serum which is used to increase accuracy of serum measures.  
 
Statistical Analysis 
 Descriptive statistics were calculated for all variables of interest. Data was analyzed 
using multiple linear regression to explore the relationship between maternal serum 25(OH)D 
and EFW and infant body composition. Covariates to be explored include maternal age, parity, 
infant gender, infant GA, maternal GWG and maternal pre-pregnancy BMI. Only significant 
variables were retained in the final model. Specific models are described with each aim below. 
Bivariate correlations were used to explore the relationships between the outcome variables of 
interest and the confounding variables. 
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All analyses were conducted using the Statistical Package for the Social Sciences (SPSS 
for windows, version 20; SPSS, Chicago, IL). For tests of significance, p<0.05 was used.  
 
Aim 1: Examine the relationship between maternal serum 25(OH)D levels measured late in 
pregnancy and fetal growth.  
 
Statistical analysis: Multiple linear regression was used to assess the relationship between 
maternal serum 25(OH)D and EFW. EFW was the outcome (dependent variable) and maternal 
serum 25(OH)D was the predictor variable (independent variable). Maternal age, parity, infant 
gender, infant GA, maternal GWG up to the time the fetal measurements were obtained and 
maternal pre-pregnancy BMI were explored. 
 
Aim 2: Examine the relationship between maternal serum 25(OH)D levels measured late in 
pregnancy and neonate body composition (%fat, FM and FFM). 
 
Statistical analysis: Multiple linear regression was used to assess the relationship between 
maternal serum 25(OH)D and infant body composition (%fat, FM and FFM). Three separate 
models were run with each infant body composition variable as the outcome variable 
(dependent) and maternal serum 25(OH)D will be the predictor variable (independent variable). 
Maternal age, parity, infant gender, infant GA, maternal total GWG was obtained and maternal 
pre-pregnancy BMI was explored.
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Chapter IV 
Results 
Study Characteristics for Body Composition Assessment 
 Combined, the Thrasher and the Epic Study contained 109 participants. Of these 
participants 45 were excluded from the study: 9 did not have a blood sample available in late 
pregnancy, 7 were excluded due to health complications such as gestational diabetes, 6 dropped 
out of the study, and 7 did not complete infant body composition analysis (Figure 2).  
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Figure 2 
Inclusion and exclusion of participants from the Epic and Thrasher Study 
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Sixty-four participants were included in the final analysis. Characteristics of the mother 
infant pairs divided by serum status can be found in Table 2. Endocrine Society ranges for serum 
status were used in descriptive tables because they are determined based on various 
physiological effects of vitamin D, as compared to IOM which sets its ranges based solely on 
vitamin D’s effect on bone mineralization (3, 85). The data set contained a majority of Caucasian 
females (23(74%), bearing male infants (36(57%)). On average participants were 29 years old at 
the infant’s birth, had blood drawn for serum analysis at 36.5 weeks gestation and had a pre-
pregnancy BMI of 25 kg/m
2
. Those that were considered to have a deficient serum vitamin D 
status had a significantly higher pre-pregnancy BMI, while no significant difference in pre-
pregnancy BMI was found between those that had insufficient and adequate serum. Furthermore, 
no significant differences were seen between serum status groups in terms of GA at serum 
analysis, GA at birth or total GWG. 
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TABLE 2 
Characteristics of mother and infant pair by serum vitamin D status 
 
Total 
(n = 63) 
Adequate 
>75nmol/L 
(n = 11) 
Insufficient 
50-75 nmol/L 
(n = 20) 
Deficient 
<50nmol/L 
(n = 32) 
p value 
Mother  
 
   
Serum 25(OH)D3 
concentration (nmol/L) 
52.6 ± 23.3 88.9 ± 13.6 61.9 ± 6.8 34.3 ± 11.2 .000 
Pre-pregnancy BMI (kg/m
2
) 25.0 ± 5.2 22.6 ±3.2 22.8 ± 4.3** 27.1 ± 5.4* 0.003 
Parity 0.55 ± 1 0.20 ± 1.3 0.17 ± 0.73 0.63 ± 1.4 0.091 
Race      
Caucasian (n (%)) 44 (69.8) 10 16 18  
African American (n 
(%)) 
10 (15.9) 1 1 8  
Hispanic (n (%)) 7 (11.1) 0 2 5  
Other (n (%)) 2 (3.2) 0 1 1  
SES      
High School or no 
qualifications 
22 10 5 7  
Some College 15 1 3 11  
4-year College 25 8 6 11  
Graduate School 11 2 6 3  
Age at child’s birth (y) 29.2 ± 4.8 31.8 ± 1.7 28.9 ± 3.6 28.6 ± 5.8 0.129 
Gestational age at blood 
draw (wk) 
36.5 ± 1.2 36.4 ± 1.3 36.3 ± 1.6 36.7 ± 1.0 0.518 
Total GWG (kg) 15.9 ± 6.3 15.4 ± 3.8 17 ± 4.8 15.45 ± 7.6 0.677 
Infant      
Male (%) 57.1% 54.5% 55% 59.4%  
Birth weight, (g) 3481 ± 395 3365 ± 297 3495 ± 418 3512 ± 413 0.563 
GA at birth, (wk) 39.6 ± 0.8 39.6 ± 0.6 39.7 ± 0.6 39.6 ± 0.9 0.868 
Age at body composition 
testing (days) 
3.4 ± 5.0 2.9 ± 2.4 3.2 ± 2.31 3.5 ± 6.7 0.927 
FM (g) 377 ± 172 356 ± 133 366 ± 159 391 ± 195 0.802 
%fat 11.2 ± 4.2 11.1 ± 3.5 10.8 ± 3.9 11.5 ± 4.7 0.832 
FFM (g) 2904 ± 311 2819 ± 173 2930 ± 345 2917 ± 329 0.611 
*value is significantly different than adequate serum group. p <0.05 
** value is significantly different than deficient serum group p <0.05 
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Correlation matrix of variables of interest 
 A correlation matrix was generated to explore the relationships between the outcome and 
predictor variables but also to explore potential relationships between confounding variables. 
The date maternal vitamin D was measured was used to create a dichotomized variable: in 
season (May to October) and out of season (November to April) representing months when the 
sun can stimulate vitamin D production in the body. This variable was not related to infant %fat, 
FM or EFW early or late. It was negatively related to infant FFM. Therefore season of measure 
will only be included as a confounding variable in the model to predict infant FFM. Vitamin D 
was negatively related to maternal pre-pregnancy BMI (r=-0.355; p=0.003). Therefore maternal 
pre-pregnancy BMI was not included in any of the models.  
 
Predictors of Infant Birth Weight 
 Relationships between infant birth weight and maternal serum 25(OH)D late in 
pregnancy were assessed using multiple linear regression analysis. The only predictor that 
remained significant in the model was GA at birth (β=171.05; p = 0.005) (Table 3). Maternal 
vitamin D was not related to infant birth weight.  
 
TABLE 3 
Predicting infant birth weight with linear regression (adjusted r
2 
= 0.10) 
(n = 63) 
 β p 
GA at birth 171.05 0.005 
p<0.05 considered as significant 
Covariates included maternal serum 25(OH)D, GA at birth, maternal total GWG, 
infant age at test and infant gender 
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Predictors of Infant Body Composition 
Percent fat 
 The relationship between infant %fat at birth and maternal 25(OH)D in late pregnancy 
was assessed using multiple linear regression analysis. Covariates included in the model were 
GA at birth, total maternal GWG, infant age at test and infant gender. Serum vitamin D did not 
remain a significant predictor of infant %fat. In the model, %fat was positively correlated with 
infant age (β=1.61; p = 0.037). An increase in age by 1 week would equal a 1.61 increase in %fat 
(Table 4).  
 
TABLE 4 
Predicting infant %fat with linear regression (adjusted r
2 
= 0.05)  
(n = 63) 
 β p 
Age at test 1.61 0.037 
p<0.05 considered as significant 
Covariates included age at test, maternal serum 25(OH)D, GA at birth, total 
GWG, and infant gender 
 
Fat Mass 
 Infant FM was positively correlated with infant age at test (β=87.45; p = 0.004). Each 
week increase in infant age correlated with an 87.45 gram increase in FM (Table 5) Covariates 
that were assessed included serum vitamin D, GA at birth, GWG, gender, and infant age at test.  
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TABLE 5 
Predicting infant FM with linear regression (adjusted r
2
= 
 
0.11) 
(n = 63) 
 β p 
Age at test 87.45 0.004 
p<0.05 considered as significant 
Covariates included age at test, maternal serum 25(OH), GA at birth, maternal 
total GWG, and infant gender 
 
Fat free mass 
 Infant FFM was predicted by the following variables: infant age at test (β= 158.24; p = 
0.001), infant GA at birth (β= 194.37; p < 0.001) and infant gender (β= -197.34; p = 0.004). In 
the dataset, males were coded as a 0 and females were coded as 1. Covariates that were assessed 
included serum vitamin D, season of blood draw, GA at birth, GWG, gender, and infant age at 
test. These results are presented in Table 6.   
 
TABLE 6 
Predicting infant FFM with linear regression (adjusted r
2
= 
 
0.33) 
(n = 63) 
 β p 
Age at Test 158.24 0.001 
Gender -197.34 0.004 
GA at birth 194.37 <0.001 
p<0.05 considered as significant 
Covariates included age at test, maternal serum 25(OH), season of blood draw*, 
GA at birth, maternal total GWG, and infant gender 
*Season of blood draw was included in this model due to association with infant 
fat free mass in correlation matrix 
 
Study Characteristics for Estimated Fetal Weight Assessment 
 Characteristics of participants included in the analysis to predict fetal weight at the early 
sonogram measurement can be found in Table 7. Out of the 64 participants included in body 
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composition analysis, 8 were excluded from analysis of EFW at early sonogram due to missing 
data. The 56 participants included have fetal weight estimated at an average of 19.9 weeks 
gestation. The population included mostly Caucasian women with some education beyond a high 
school diploma.  There were no significant differences in parity, or GA at assessment between 
serum classification groups. Pre-pregnancy BMI was significantly different between the 
adequate and deficient group, as well as the insufficient and deficient group.  
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TABLE 7 
Characteristics of mother and fetal measurements at early sonogram measurements 
 
Total 
(n = 56) 
Adequacy 
>75nmol/L 
(n = 9) 
Insufficient 
50-75nmol/L 
(n = 19) 
Deficient 
<50nmol/L 
(n = 28) 
p value 
Mother  
 
   
Serum 25(OH)D3 
concentration (nmol/L) 
52.1 ± 23.6 90.0 ± 15.0 61.4 ± 6.6 33.5 ± 11.8 0.000 
Pre-pregnancy BMI 
(kg/m
2
) 
24.6 ± 4.8 23.0 ± 3.5 22.6 ± 4.4** 26.4 ± 4.8 0.015 
Parity 0.70 ± 0.8 0.67 ± 0.9 0.47 ± 0.6 0.86 ± 0.8 0.261 
Race      
Caucasian (n (%)) 38 8 16 14  
African American 
(n (%)) 
10 1 1 8  
Hispanic (n (%)) 7 0 2 5  
Other (n (%)) 1 0 0 1  
SES      
High School or no 
qualifications 
10 0 5 5  
Some College 15 1 3 11  
4-year College 22 7 6 9  
Graduate School 9 1 5 3  
Age at child’s birth (y) 28.8 ± 4.7 31.7 ± 1.8 286 ± 3.6 28.1 ± 5.7 0.133 
GA at blood draw (wk) 36.3 ± 1.2 36.2 ± 1.5 36.2 ± 1.5 36.7 ± 1.0 0.360 
GWG up to sonogram 
measurement 
5.4 ± 4.5 3.7 ± 2.3 5.0 ± 3.6 6.1 ± 5.5 0.389 
Male (%) 58.9% 66.6% 63.2% 53.6%  
GA at Sonogram 
measurement 
19.9 ± 1.7 19.3 ± 2.0 19.7 ± 1.4 20.2 ± 1.7 0.302 
EFW 339 ± 111 298 ± 121 320 ± 88 363 ± 120 0.239 
*value is significantly different than adequate serum group. p <0.05 
** value is significantly different than deficient serum group p <0.05 
 
Only 31 of the included participants had an estimation of fetal weight late in pregnancy. 
Characteristics of these women can be located in Table 8. Of these women there were no 
significant differences between pre-pregnancy BMI, GWG or GA at sonogram measurements. 
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Participants who were classified as deficient had blood analysis that was significantly later in 
gestation than those that were insufficient. No association was found between the adequate and 
deficient groups or adequate and insufficient groups.   
 
TABLE 8 
Characteristics of mother and fetal measurements at late sonogram measurements 
 
Total 
(n = 31) 
Adequacy 
>75nmol/L 
(n = 6) 
Insufficient 
50-75nmol/L 
(n = 11) 
Deficient 
<50nmol/L 
(n = 14) 
p value 
Serum 25(OH)D3 
concentration (nmol/L) 
52.7 ± 24.4 87.6 ± 11.9 61.5 ± 7.0 30.8 ± 11.6 0.000 
Pre-pregnancy BMI 
(kg/m
2
) 
24.8 ± 5.4 23.6 ± 4.3 22.5 ± 4.7 27.0 ± 5.6 0.084 
Parity 0.58 ± 0.7 0.33 ± 0.5 0.36 ± 0.5 0.86 ± 0.7 0.113 
Race      
Caucasian (n (%)) 23 6 9 8  
African American (n 
(%)) 
6 0 2 4  
Hispanic (n (%)) 2 0 0 2  
Other (n (%)) 0 0 0 0  
SES      
High School or no 
qualifications 
7 0 3 4  
Some College 6 0 2 4  
4-year College 10 5 1 4  
Graduate School 8 1 5 2  
Age at child’s birth (y) 28.7 ± 4.6 31.4 ± 1.8 28.1 ± 3.7 28.0 ± 5.7 0.288 
GA at blood draw (wk) 36.3 ± 1.2 36.3 ± 0.7 35.6 ± 1.6 36.8 ± 0.7 0.039 
GWG up to sonogram 
measurement 
14.7 ± 6.1 12.8 ± 3.0 13.7 ± 5.0 16.3 ± 7.6 0.404 
Male (%) 54.8% 33.3 % 54.5 % 64.3 %  
GA at Sonogram 
measurement 
35.3 ± 2.7 35.5 ± 2.4 35.3 ± 1.3 35.1 ± 3.7 0.952 
EFW 2623 ± 663 2423 ± 502 2688 ± 584 2658 ± 795 0.722 
*value is significantly different than adequate serum group. p <0.05 
** value is significantly different than deficient serum group p <0.05 
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Predictors of Estimated Fetal Weight 
 The relationship between maternal serum 25(OH)D and EFW was assessed using 
multiple linear regression analysis. Covariates included were GA at sonogram measurement, 
GWG up to sonogram measurement and infant gender. Estimated fetal weight early in pregnancy 
was predicted by GA at sonogram measurement (β=62.57; p <0.001) and GWG up to the 
sonogram (β= -3.84; p=0.006) (Table 9). 
 
TABLE 9 
Predicting EFW early in pregnancy with linear regression (adjusted r
2 
=
 
0.86) 
(n = 56) 
 β p 
GWG at measurement - 3.84  0.006 
GA at measurement 65.65 <0.001 
p<0.05 considered as significant 
Covariates included serum 25(OH)D late in pregnancy, GA at measurement, 
GWG at measurement, and infant gender 
 
 Fetal weight estimated later in pregnancy was predicted by GA at sonogram (β=207.81; p 
< 0.001). Maternal serum 25(OH)D approached significance (β=-4.42; p = 0.090). When 
maternal vitamin D was dropped from the model, GA at sonogram remained significant. (Table 
10).  
 
TABLE 10 
Predicting EFW late in pregnancy with linear regression (adjusted r
2 
= 0.83 ) 
(n = 31 
 β p 
GA at sonogram  208.83 <0.001 
p<0.05 considered as significant 
Covariates included serum 25(OH)D late in pregnancy, GA at measurement, 
GWG at measurement, and infant gender 
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Chapter V 
Discussion 
 The purpose of this study was to explore the relationship between maternal vitamin D 
levels to fetal growth and infant body composition at birth. Within this data set, maternal serum 
25(OH)D was not significantly correlated with EFW in pregnancy, infant birth weight or infant 
body composition. These results vary from the literature in multiple ways.  
 
Birth Weight and Body Composition and Serum Vitamin D 
Infant birth weight 
 In our sample, serum 25(OH)D was not a predictor of infant birth weight. We found that 
maternal pre-pregnancy BMI and GA predicted infant birth weight. The body of literature is 
mixed with some studies finding differences (9-11, 14, 16, 61, 73) while other studies have 
found no relationship between vitamin D levels and birth weight (12, 13, 15, 17-19, 77). 
Gestational age at serum measurement may affect the association between serum 
25(OH)D and birth weight. Gale et al analyzed serum 25(OH)D in 466 women late in pregnancy. 
The population of this study was similar to that of our study and it also found no association with 
birth weight. While Gernand et al measured serum 25(OH)D in the first and second trimester, 
and only found a negative relationship with birth weight in the first trimester. This is similar to 
results found in other studies that assessed serum 25(OH)D before 28 weeks gestation (10, 11, 
61). It could be suggested that early serum vitamin D may contribute to a growth trajectory set in 
early gestation. This theory has been supported in other studies of physiological factors of 
growth (86).   
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Furthermore, studies that found an association between birth weight and serum 25(OH)D 
had over 1000 participants. Moller et al assessed serum 25(OH)D in 92 planned pregnancies at 
11, 22, and 35 weeks GA and found no association (17). Leffelaar et al assessed 3730 women at 
less than 12 weeks gestation and also found an association (61).  In multiple studies, low serum 
26(OH)D increases the risk of delivering an infant that is small-for-gestational age (10, 11, 61). 
The relationship may not be detectable within a small cohort.  
 
Infant body composition 
 In our sample, infant %fat correlated infant age at test. An association between infant age 
and infant %fat was expected due to the change in infant body composition after birth.    
One study has analyzed serum 25(OH)D and infant body composition at birth in a similar 
manner. Crozier et al saw a correlation between serum vitamin D and %fat at birth. Our study 
and Crozier’s analysis differ significantly in methodology. Crozier assessed infant FM using dual 
energy x-ray absorptiometry within 3 weeks of life. Our study assessed infant FM using air 
displacement plethysmography within 3 days of life. Variation between body composition 
analysis tools is likely minimal (87). However, time of analysis makes these two studies quite 
different. Statistical models from Crozier et al. did not account for infant weight change from 
birth to test, feeding methods and other covariates that may affect a child’s body composition 
early in life (8).After a few weeks of life these factors may contribute to infant body composition 
changes and confound the ability to assess relationships between the maternal in utero 
environment and infant outcomes.   
In our study, infant FFM at birth was significantly predicted by age, gender, and GA, 
which was expected. Within the last weeks of gestation and first weeks of life, infant rate of 
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growth is quite rapid, thus increasing FFM with age. This is further supported by research which 
measured infant body composition by week (88). Gender differences in %fat at birth have been 
reported. In 2009 Fields et al, found a difference in %fat and FFM based on gender. However, 
this difference no longer existed at 6 months of age (89) 
 
Estimated Fetal Weight and Serum Vitamin D 
 No published research studies have assessed the relationship between EFW and serum 
25(OH)D status. As suspected in both late and early sonogram measurements, GA was a 
significant predictor of fetal weight. Furthermore, estimation of fetal weight varies greatly after 
the first trimester therefore it may take a large sample size to detect differences between groups. 
In a systematic review, N.J Dudley emphasizes that the random errors within estimating fetal 
weight cause it to have limited accuracy and sensitivity (90). Factors affecting these errors 
include observer error, image quality, equipment calibration and measurement methods.  
 Estimated fetal weight early in pregnancy was negatively associated with GWG and 
positively associated with GA at measurement. Though this may seem like a counterintuitive 
relationship, with further analysis a logical explanation may be obvious. Maternal pre-pregnancy 
BMI was not related to early EFW. When you look at the mean maternal GWG per week at the 
early sonogram, there are dramatic differences by pre-pregnancy BMI. The values for normal, 
overweight and obese are 0.25, 0.48 and 0.17 kg/week, respectively. The negative relationship 
with maternal GWG may be reflective of an underlying relationship within the maternal pre-
pregnancy groups where an obese maternal pre-pregnancy BMI in light of a low early weight 
gain still programs a larger fetus. 
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Limitations and Strengths 
 Unavoidable limitations are contained within this study. First, EFW was assessed by a 
trained but not certified study coordinator. This is due to lack of certified sonographer 
availability and monetary costs associated with it. The sample size included in the study is small 
and we may not have enough power to detect differences caused by serum vitamin D. We were 
only able to assess maternal vitamin D status late in pregnancy therefore making the assumption 
that the maternal vitamin D levels assessed late in pregnancy were representative of the maternal 
vitamin D status early in pregnancy. Research has suggested that maternal vitamin D does 
increase across pregnancy (60). Therefore the level we measured late in pregnancy may be 
underestimating a true relationship as a late measured value is likely greater than what would 
have been measured early in pregnancy.   
 There are also several strengths of this study. Maternal vitamin D was analyzed by serum 
which accounts for vitamin D that is synthesized in the skin and obtained from the diet. Our 
sample included a wide range of serum vitamin D concentrations from 12 to 120 nmol/L. 
Another strength of the study is that body composition of infants was measured using air-
displacement plethysmography. This method is accurate, safe and easy measure infant FM, FFM, 
and %fat (82-84). Infant body composition was also assessed within 72 hours of life. This helped 
to avoid any effects of infant feeding or growth that may occur within the first weeks of life.  
 
Conclusions 
 In our sample, serum 25(OH)D late in pregnancy did not predict infant birth weight, 
EFW, or body composition at birth. A review of the literature suggests that serum 25(OH)D’s 
role in fetal growth is observable in large cohorts and when serum 25(OH)D is assessed early in 
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gestation. More research is required in order to investigate the potential role of early serum 
25(OH)D on programming the fetal growth trajectory. Future research should assess a large 
cohort of women at less than 28 weeks gestation. Inclusion of EFW in this research may provide 
a greater insight to how a fetus develops differently in mothers of adequate or deficient status. 
Early detection of insufficient fetal growth related to insufficient 25(OH)D could provide 
mothers with the ability to correct status and possible improve birth outcomes.   
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APPENDIX 
 
 
  
TABLE 1 
Recommended serum 25(OH)D in pregnancy and daily vitamin D intake to achieve those levels  
 Serum 25(OH)D Intake Upper limit 
Institute of Medicine  >50 nmol/L 600 IU 4,000 IU 
Endocrine Society >75 nmol/L 1,500-2,000 IU 10,000 IU 
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 Figure 1 A-C 
A. Image of fetal head, biparietal diameter represented by 
solid line, and circumference represented by dashed 
line. The cavum septum pellucidum is indicated (CSP) 
B. Image for measurement of fetal abdomen 
circumference. An arrow indicates the junction of the 
umbilical vein and portal sinus. The spine is located on 
the right and the stomach is the dark portion at the 
bottom of the image.  
C. Image of the fetal femur indicating a proper 
measurement along the length of the bone. 
Images obtained from Obstetrics: Normal and Problem 
Pregnancies, 6
th
 ed. ©
 
2012 (80)  
  
A 
A B 
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Figure 2 
Inclusion and exclusion of participants from the Epic and Thrasher Study 
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TABLE 2 
Characteristics of mother and infant pair by serum vitamin D status 
 
Total 
(n = 63) 
Adequate 
>75nmol/L 
(n = 11) 
Insufficient 
50-75 nmol/L 
(n = 20) 
Deficient 
<50nmol/L 
(n = 32) 
p value 
Mother  
 
   
Serum 25(OH)D3 
concentration (nmol/L) 
52.6 ± 23.3 88.9 ± 13.6 61.9 ± 6.8 34.3 ± 11.2 .000 
Pre-pregnancy BMI (kg/m
2
) 25.0 ± 5.2 22.6 ±3.2 22.8 ± 4.3** 27.1 ± 5.4* 0.003 
Parity 0.55 ± 1 0.20 ± 1.3 0.17 ± 0.73 0.63 ± 1.4 0.091 
Race      
Caucasian (n (%)) 44 (69.8) 10 16 18  
African American (n 
(%)) 
10 (15.9) 1 1 8  
Hispanic (n (%)) 7 (11.1) 0 2 5  
Other (n (%)) 2 (3.2) 0 1 1  
SES      
High School or no 
qualifications 
22 10 5 7  
Some College 15 1 3 11  
4-year College 25 8 6 11  
Graduate School 11 2 6 3  
Age at child’s birth (y) 29.2 ± 4.8 31.8 ± 1.7 28.9 ± 3.6 28.6 ± 5.8 0.129 
Gestational age at blood 
draw (wk) 
36.5 ± 1.2 36.4 ± 1.3 36.3 ± 1.6 36.7 ± 1.0 0.518 
Total GWG (kg) 15.9 ± 6.3 15.4 ± 3.8 17 ± 4.8 15.45 ± 7.6 0.677 
Infant      
Male (%) 57.1% 54.5% 55% 59.4%  
Birth weight, (g) 3481 ± 395 3365 ± 297 3495 ± 418 3512 ± 413 0.563 
GA at birth, (wk) 39.6 ± 0.8 39.6 ± 0.6 39.7 ± 0.6 39.6 ± 0.9 0.868 
Age at body composition 
testing (days) 
3.4 ± 5.0 2.9 ± 2.4 3.2 ± 2.31 3.5 ± 6.7 0.927 
FM (g) 377 ± 172 356 ± 133 366 ± 159 391 ± 195 0.802 
%fat 11.2 ± 4.2 11.1 ± 3.5 10.8 ± 3.9 11.5 ± 4.7 0.832 
FFM (g) 2904 ± 311 2819 ± 173 2930 ± 345 2917 ± 329 0.611 
*value is significantly different than adequate serum group. p <0.05 
** value is significantly different than deficient serum group p <0.05 
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TABLE 3 
Predicting infant birth weight with linear regression (adjusted r
2 
= 0.10) 
(n = 63) 
 β p 
GA at birth 171.05 0.005 
p<0.05 considered as significant 
Covariates included maternal serum 25(OH)D, GA at birth, maternal total GWG, 
infant age at test and infant gender 
 
 
TABLE 4 
Predicting infant %fat with linear regression (adjusted r
2 
= 0.05)  
(n = 63) 
 β p 
Age at test 1.61 0.037 
p<0.05 considered as significant 
Covariates included age at test, maternal serum 25(OH)D, GA at birth, total 
GWG, and infant gender 
 
 
TABLE 5 
Predicting infant FM with linear regression (adjusted r
2
= 
 
0.11) 
(n = 63) 
 β p 
Age at test 87.45 0.004 
p<0.05 considered as significant 
Covariates included age at test, maternal serum 25(OH), GA at birth, maternal 
total GWG, and infant gender 
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TABLE 6 
Predicting infant FFM with linear regression (adjusted r
2
= 
 
0.33) 
(n = 63) 
 β p 
Age at Test 158.24 0.001 
Gender -197.34 0.004 
GA at birth 194.37 <0.001 
p<0.05 considered as significant 
Covariates included age at test, maternal serum 25(OH), season of blood draw*, 
GA at birth, maternal total GWG, and infant gender 
*Season of blood draw was included in this model due to association with infant 
fat free mass in correlation matrix 
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TABLE 7 
Characteristics of mother and fetal measurements at early sonogram measurements 
 
Total 
(n = 56) 
Adequacy 
>75nmol/L 
(n = 9) 
Insufficient 
50-75nmol/L 
(n = 19) 
Deficient 
<50nmol/L 
(n = 28) 
p value 
Mother  
 
   
Serum 25(OH)D3 
concentration (nmol/L) 
52.1 ± 23.6 90.0 ± 15.0 61.4 ± 6.6 33.5 ± 11.8 0.000 
Pre-pregnancy BMI 
(kg/m
2
) 
24.6 ± 4.8 23.0 ± 3.5 22.6 ± 4.4** 26.4 ± 4.8 0.015 
Parity 0.70 ± 0.8 0.67 ± 0.9 0.47 ± 0.6 0.86 ± 0.8 0.261 
Race      
Caucasian (n (%)) 38 8 16 14  
African American 
(n (%)) 
10 1 1 8  
Hispanic (n (%)) 7 0 2 5  
Other (n (%)) 1 0 0 1  
SES      
High School or no 
qualifications 
10 0 5 5  
Some College 15 1 3 11  
4-year College 22 7 6 9  
Graduate School 9 1 5 3  
Age at child’s birth (y) 28.8 ± 4.7 31.7 ± 1.8 286 ± 3.6 28.1 ± 5.7 0.133 
GA at blood draw (wk) 36.3 ± 1.2 36.2 ± 1.5 36.2 ± 1.5 36.7 ± 1.0 0.360 
GWG up to sonogram 
measurement 
5.4 ± 4.5 3.7 ± 2.3 5.0 ± 3.6 6.1 ± 5.5 0.389 
Male (%) 58.9% 66.6% 63.2% 53.6%  
GA at Sonogram 
measurement 
19.9 ± 1.7 19.3 ± 2.0 19.7 ± 1.4 20.2 ± 1.7 0.302 
EFW 339 ± 111 298 ± 121 320 ± 88 363 ± 120 0.239 
*value is significantly different than adequate serum group. p <0.05 
** value is significantly different than deficient serum group p <0.05 
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TABLE 8 
Characteristics of mother and fetal measurements at late sonogram measurements 
 
Total 
(n = 31) 
Adequacy 
>75nmol/L 
(n = 6) 
Insufficient 
50-75nmol/L 
(n = 11) 
Deficient 
<50nmol/L 
(n = 14) 
p value 
Serum 25(OH)D3 
concentration (nmol/L) 
52.7 ± 24.4 87.6 ± 11.9 61.5 ± 7.0 30.8 ± 11.6 0.000 
Pre-pregnancy BMI 
(kg/m
2
) 
24.8 ± 5.4 23.6 ± 4.3 22.5 ± 4.7 27.0 ± 5.6 0.084 
Parity 0.58 ± 0.7 0.33 ± 0.5 0.36 ± 0.5 0.86 ± 0.7 0.113 
Race      
Caucasian (n (%)) 23 6 9 8  
African American (n 
(%)) 
6 0 2 4  
Hispanic (n (%)) 2 0 0 2  
Other (n (%)) 0 0 0 0  
SES      
High School or no 
qualifications 
7 0 3 4  
Some College 6 0 2 4  
4-year College 10 5 1 4  
Graduate School 8 1 5 2  
Age at child’s birth (y) 28.7 ± 4.6 31.4 ± 1.8 28.1 ± 3.7 28.0 ± 5.7 0.288 
GA at blood draw (wk) 36.3 ± 1.2 36.3 ± 0.7 35.6 ± 1.6 36.8 ± 0.7 0.039 
GWG up to sonogram 
measurement 
14.7 ± 6.1 12.8 ± 3.0 13.7 ± 5.0 16.3 ± 7.6 0.404 
Male (%) 54.8% 33.3 % 54.5 % 64.3 %  
GA at Sonogram 
measurement 
35.3 ± 2.7 35.5 ± 2.4 35.3 ± 1.3 35.1 ± 3.7 0.952 
EFW 2623 ± 663 2423 ± 502 2688 ± 584 2658 ± 795 0.722 
*value is significantly different than adequate serum group. p <0.05 
** value is significantly different than deficient serum group p <0.05 
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TABLE 9 
Predicting EFW early in pregnancy with linear regression (adjusted r
2 
=
 
0.86) 
(n = 56) 
 β p 
GWG at measurement - 3.84  0.006 
GA at measurement 65.65 <0.001 
p<0.05 considered as significant 
Covariates included serum 25(OH)D late in pregnancy, GA at measurement, 
GWG at measurement, and infant gender 
 
 
TABLE 10 
Predicting EFW late in pregnancy with linear regression (adjusted r
2 
= 0.83 ) 
(n = 31 
 β p 
GA at sonogram  208.83 <0.001 
p<0.05 considered as significant 
Covariates included serum 25(OH)D late in pregnancy, GA at measurement, 
GWG at measurement, and infant gender 
 
